Amylyx Pharmaceuticals Financial Statements
NASDAQ: AMLXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Amylyx Pharmaceuticals revenue and earnings
In fiscal 2025, Amylyx Pharmaceuticals generated $0 in revenue, down 100.0% from fiscal 2024, its first annual decline since 2024. Amylyx Pharmaceuticals reported a net loss of $144.7 million, compared with a loss of $301.7 million a year earlier. Diluted earnings per share came in at -$1.53.
Summary generated from market data by MetaCap's automated system. Methodology
Amylyx Pharmaceuticals income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 |
|---|---|---|---|---|---|
| Revenue | 0 | 87.37M | 380.79M | 22.23M | 285.00K |
| Revenue growth (YoY) | -100.00% | -77.06% | +1612.94% | +7700.00% | — |
| Cost of Revenue | 0 | 5.95M | 25.44M | 2.99M | — |
| Gross Profit | 0 | 81.42M | 355.35M | 19.24M | — |
| Operating Expenses | 153.29M | 396.15M | 316.54M | 220.58M | — |
| Research & Development | 90.40M | 104.08M | 128.19M | 93.45M | 44.04M |
| Selling, General & Admin | 62.89M | 114.33M | 188.36M | 127.13M | 38.93M |
| Operating Income | -153.29M | -314.73M | 38.80M | -201.34M | -82.69M |
| Other Income (Expense) | 8.60M | 12.60M | 15.49M | 3.74M | -5.24M |
| Pretax Income | -144.69M | -302.14M | 54.30M | -197.60M | -87.93M |
| Income Tax | 46.00K | -393.00K | 5.03M | 774.00K | — |
| Net Income | -144.74M | -301.74M | 49.27M | -198.38M | -87.93M |
| Net Income growth (YoY) | — | -712.42% | — | — | — |
| EPS (Basic) | -1.53 | -4.43 | 0.73 | -3.39 | -13.35 |
| EPS (Diluted) | -1.53 | -4.43 | 0.70 | -3.39 | -13.35 |
| Shares Outstanding (Basic) | 94.57M | 68.14M | 67.23M | 58.50M | 6.59M |
| Shares Outstanding (Diluted) | 94.57M | 68.14M | 69.99M | 58.50M | 6.59M |
| EBITDA | -152.77M | -313.83M | 39.89M | -200.85M | -82.64M |
| Gross Margin | — | 93.19% | 93.32% | 86.54% | — |
| Operating Margin | — | -360.22% | 10.19% | -905.72% | -29013.33% |
| Net Margin | — | -345.36% | 12.94% | -892.38% | -30852.98% |
This table shows 5 annual periods of Amylyx Pharmaceuticals's income statement, from FY 2025 back to FY 2021, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow AMLX's reporting calendar. What is a income statement?